ERYP.PA

Compare

No price history available for this symbol yet.

Fair-value model

Consensus-seeded revenue, margins, and exit multiples. This is a scenario tool, not investment advice.

Years of analysisAssumption entries

Analyst estimates unavailable for this ticker.

Held by

portfolios on TandT

Bookmarked by

users

Avg position size

—

of holders' portfolios

13F filers

institutions

Sector

Biotechnology

Earnings surprises

Beat consensus in 3 of the last 4 reported quarters

Reported	Est. EPS	Actual	Surprise
2023-03-28	$-0.18	$0.19	+205.6%
2022-09-12	$-0.56	$-0.11	+80.4%
2022-05-12	$-0.47	$-0.38	+19.1%
2021-09-20	$-0.59	$-0.74	-25.4%

Peer comparison

Symbol	Price	Today	Mkt cap	P/E
ERYP.PAERYTECH Pharma S.A.	$0.80	+0.25%	$49M	—
ALNEV.PANeovacs S.A.	$0.26	-7.14%	$12	—
ALPHE.PAPherecydes Pharma S.A.	$2.00	-0.50%	$16M	—
ALQGC.PAQuantum Genomics S.A.	$0.07	+0.00%	$5M	—
ALVET.PATheraVet S.A.	$0.08	+0.00%	$10M	—
ALVMG.PAVisiomed Group S.A.	$0.17	-1.82%	$53M	—
APM.PAAptorum Group Limited	$3.21	+0.00%	$9M	—

Source: Financial Modeling Prep · peers by sector/industry

ERYTECH Pharma S.A.

ERYTECH Pharma S.A. is a clinical-stage biopharmaceutical company focused on creating innovative therapies derived from red blood cells. These treatments target various types of cancer and rare (orphan) diseases, with the company operating in both France and the United States. Its primary experimental drug, eryaspase, is currently undergoing Phase 3 clinical trials for patients battling second-line pancreatic cancer. Furthermore, this candidate is also in Phase 2 development for triple-negative breast cancer and for individuals with second-line acute lymphoblastic leukemia. The company is additionally advancing erymethionase, a preclinical-stage product. This candidate utilizes methionine-gamma-lyase, encased within red blood cells, to specifically address cancers that are dependent on methionine for growth. Established in 2004, ERYTECH Pharma's corporate headquarters are situated in Lyon, France.

www.erytech.com

Employees: 49
IPO / List date: May 7, 2013
HQ: FR

Held by traders on TradeandTell

No one on the platform currently holds ERYP.PA.

Super investors & insiders

Institutions holding (13F)

No tracked institution reports a position in ERYP.PA as of their last filing.

Insider activity (SEC Form 4)

No recent Form 4 filings on EDGAR — either no insider transactions reported recently or this isn't a SEC-registered issuer.

Insider activity (SEC Form 4)

Recent trades on TradeandTell

No one on the platform has traded ERYP.PA yet.